title: Effects of dapiprazole, clonidine and yohimbine on the development of dependence and withdrawal behaviour in mice.
abstract: There is evidence that central noradrenergic hyperactivity is involved in the manifestation of the major signs and symptoms of the opiate withdrawal syndrome. In order to assess whether or not the noradrenergic system is also implicated in the development of opiate dependence, we studied dapiprazole, an alpha-1 selective adrenoceptor antagonist, clonidine and yohimbine using the acute dependence model in mice. When administered just before naloxone, after dependence development, all three drugs reduce abstinence signs. When injected 15 min before morphine to observe the drugs' effects on the development of dependence, dapiprazole depresses all the symptoms registered while clonidine decreases only jumping, but increases paw and head shakes. None of these drugs affects the naloxone precipitated withdrawal syndrome when injected 1 h before morphine. It is suggested that the noradrenergic system is involved in both the manifestation of the withdrawal syndrome and in the development of opiate dependence. Diapiprazole may be a useful tool in patients and in pharmacological studies of dependence and abstinence.
authors.affiliation: Institute of Pharmacology and Pharmacognosy, University of Rome La Sapienza, Italy.
authors.forename: P
authors.initials: P
authors.lastname: Valeri
authors.forename: B
authors.initials: B
authors.lastname: Martinelli
authors.forename: G
authors.initials: G
authors.lastname: Pimpinella
authors.forename: C
authors.initials: C
authors.lastname: Severini
mesh_terms: D000818:Animals; D001522:Behavior, Animal / Q000187:drug effects; D001921:Brain / Q000187:drug effects; D003000:Clonidine / Q000627:therapeutic use*; D004305:Dose-Response Relationship, Drug; D007276:Injections, Intraventricular; D008297:Male; D051379:Mice; D008815:Mice, Inbred Strains; D009021:Morphine Dependence / Q000534:rehabilitation*; D009270:Naloxone / Q000627:therapeutic use; D010879:Piperazines; D013375:Substance Withdrawal Syndrome / Q000534:rehabilitation*; D014230:Triazoles / Q000627:therapeutic use*; D015016:Yohimbine / Q000627:therapeutic use*
chemical_list: D010879:Piperazines; D014230:Triazoles; D015016:Yohimbine; D009270:Naloxone; C035289:dapiprazole; D003000:Clonidine